Sangel Capital

  • Predicine closes RMB100m Series B1 round of strategic financing

    On July 29th, Predicine announced that it had completed the Series B1 strategic financing round of more than 100 million yuan.
    The round was led by Bayland Capital, with participation from existing investors Highlight Capital and Sangel Capital.

  • Denovo Biopharma nets nearly RMB600m in Series C round

    Precision medicine company Denovo Biopharma announced the completion of a 590 million yuan Series C round of financing on June 29.
    The round was led by Zhongjin Qide Innovative Biomedical Equity Investment Fund, with participation from existing investors Jiuyou Capital, Share Capital, CITIC Securities and Sangel Capital, as well as new investors including Yingke PE, Guozhong Capital, among other